*** SHMN S/S TA Share structure as of 09/03/2020 ***
Authorized: 2,000,000,000
Issued: 1,575,576,407
Restricted: 327,792,017
UnRestricted 1,247,784,390
*** SHMN S/S TA Share structure as of 12/09/2019 ***
Authorized: 2,000,000,000
Issued: 1,561,687,518
*** SHMN S/S TA Share structure as of 12/02/2019 ***
Authorized: 2,000,000,000
Issued: 1,547,798,629
Restricted: 300,014,239
"---below maintained by imgoingfishing1"
SOHM, Inc.
SHMN
About
Sohm, Inc. is a globally recognized Pharmaceutical company focused on developing, manufacturing and distributing Generic, Branded Generic, Private label, and Sohm innovated Pharmaceuticals, Cosmeceuticals and Nutraceutical products. The Company has its U.S. headquarters located in Buena Park, CA with international headquarters (Sohm India Pvt Ltd) located in Ahmedabad, India as well as several corporate offices located within the UK and China.
Sohm Inc. was voted the fastest growing generics prescription drug manufacturer in 2012 at the 30th All India Conference of National Integrated Medical Association. Sohm develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in several countries.
Sohm is committed to strict adherence of all applicable regulatory requirements and to the highest degree of industry standards. We are committed to maintaining quality by all employees at all levels throughout our corporation. Sohm ensures compliance by continuous assessment and monitoring of the output of the existing quality systems, and application of evolving industry guidelines and regulations including all WHO-CGMP and USFDA guidelines.
Sohm also offers and encourages businesses of any size all over the world to participate with the private labeling of generic pharmaceutical, cosmeceutical and nutraceutical products as part of its ongoing effort to integrate businesses and inspire global prosperity.
Investors
The Board of Directors of SOHM, Inc. believes that shareholder confidence in the Company, its management and financial reporting is critical to the success of the Company. This website provides general information regarding the corporate business activities of the Company. Further information can be obtained at www.otcmarkets.com
The Board also believes that good governance practice enhances confidence in our management team, financial information and employees. It creates a solid foundation for achieving our business goals and enables the Company to operate at the highest ethical standards. The Board has adopted actions that seek to ensure full compliance with the listing standards of the pinksheets electronic listing service.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
NEW CEO
September 10, 2018
CURRENT NEWS/FILINGS
https://www.otcmarkets.com/stock/SHMN/news
https://www.sohm.com/category/press-releases/
2/26/2019
New Filing!!!!!!!!
SHMN FILES Share BuyBack Program
Supplemental Information - SOHM, INC., ANNOUNCES SHARES BUYBACK PROGRAM
https://backend.otcmarkets.com/otcapi/company/financial-report/212433/content
2/26/2019
News
SOHM, INC., ANNOUNCES SHARES BUYBACK PROGRAM
CHINO HILLS, CA / ACCESSWIRE / February 26, 2019 / SOHM, Inc. (OTC PINK: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that its Board of Directors has formally approved the initiation of a common stock share buyback program.
SOHM remains focused on continuing efforts to revitalize its business operations, while simultaneously seeking to ensure that the current and potential shareholders remain apprised of ongoing initiatives - all of which will help to ensure our ongoing commitment to maximizing shareholder value.
Accordingly, Mr. Baron Night, President and CEO notes that "we acknowledge that SOHM's current cap structure is not optimal. Instead of a reverse split, we would rather begin taking concrete steps to reduce the company's current outstanding shares while ensuring that our investors do not see their holdings reduced. To that end, the Board of Directors has agreed to engage in a public market based common stock share buyback program."
The buyback program as currently planned will take place between March 1, 2019 and February 28, 2021, with an initial target of 10% of the current outstanding shares of SOHM, Inc. common stock (approximately 154,000,000 shares), with not less than 50% to be retired. Pursuant to the safe harbor provisions of Rule 10b-18, these shares will be acquired by SOHM on the public market, and will be subject to the manner of purchase, timing, price, and volume restrictions specified therein.
SOHM's plan to repurchase these shares is subject to change at any time upon adequate public notice, with the number of shares and definitive timeline to be decided by market conditions and the company's financial status. Any changes to this plan will be noticed via press release and/or filing with OTC Public Markets.
https://www.otcmarkets.com/stock/SHMN/news/Sohm-Inc-Announces-Shares-Buyback-Program?id=219520
January 18, 2019
SOHM, Inc. Announce Share Holder Update and Outlook for 2019
CHINO HILLS, CA / ACCESSWIRE / January 18, 2019 / SOHM, Inc. (OTC PINK: SHMN), a generic Pharmaceutical, Nutraceutical and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today some of developments with the company which it started during 2017 and 2018 regarding the outlook of the company for the year 2019 and beyond in their reentry into the US OTC retail, prescription, contract manufacturing and white label manufacturing and marketing space.
SOHM, Inc. has been working with partners since August 2017 to optimize SOHM's OTC, nutraceutical and prescription products of its customer and own product sell-through distribution partners in the huge retail and convenience store segments. As part of the process, the company has made several alliance agreements and contracts with suppliers as well as customers during 2018 and same were updated through its press releases.
Furthermore, SOHM's OTC generic as well as skin care products were introduced into the USA market between the year 2012 and 2015, however, due to the heart attack and health leave of its then CEO, the appropriate project launch was not carried out and was not followed up by the company the way it was planned for several years. Now the company has been working and reviving its old distribution channels again during the year 2019 where SOHM's OTC products were tested on shelves back in 2nd and 3rd quarters of the year 2014. The company had received a very good response on its pilot project.
The company also is in negotiation with one of pharma company for the development of new products for them as well as for SOHM and is working to introduce and plans to launch some more new product segments in this year which is going to enhance the company's ability to generate sustainable revenue and rapid growth in 2019 and for the coming years.
Mr. Baron Night, President and CEO today states that SOHM has a very good and encouraging operation going on along with a good response from its existing contract and white label manufacturing customers. The company expects some more orders from them during this quarter as stated earlier. Mr. Night states that this development will help the company go beyond its current revenues and profitability during 2019.
The management anticipates and expects its revenue growth more than doubling during the year 2019 compared to the year 2018 and overall profitability of around 38% during the year 2019.
The management is not intending to conduct any reverse split but in coming days/weeks and months, the company will be considering a share buyback program. The company is in communication with its counsel and at the appropriate time, the company may make an announcement, if the company decides to pursue a buyback program after appropriate due diligence and consultation from our legal counsel. Current revenue and orders are enough for its ongoing smooth operations. We are working as per our goals and plan as stated earlier in our previous press release on September 21, 2018.
The company has remained transparent previously and we are committed for transparency within guidelines and rules and working consistently towards it. "Our operational and revenue generation efforts are ongoing, and we are confident of achieving our revenue target for the year 2019 and beyond", stated Mr. Night, President and CEO.
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-Share-Holder-Update-and-Outlook-for-2019?id=215966
January 7, 2019
SOHM, Inc., Enters into Master Supply Agreement with US based Pharmaceutical Company
CHINO HILLS, CA / ACCESSWIRE / January 7, 2019 / SOHM, Inc. (OTC PINK: SHMN), a generic Pharmaceutical, Nutraceutical and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today the signing of a MASTER SUPPLY AGREEMENT with a US based customer to supply their OTC and Prescription (Rx) products. The manufacturing will be done through current agreements between SOHM and USA based facilities.
Mr. Baron Night, CEO, states that this new master supply agreement, when added to SOHM's 2019 products portfolio, will contribute significantly to the company's future overall growth. This agreement is just the beginning of SOHM's recent strategy, adopted by previous management, to smoothly increase its USA based manufacturing capabilities. This agreement is the result of persistent hard work by SOHM's predecessor as well as its sales and marketing team. The company's year 2019 revenue growth is expected up to 95% above the year 2018 figures.
Currently, SOHM expects more than 7 to 9 SKU orders from this customer. An updated shareholders outlook for the year 2019 should be released shortly.
Mr. Night and management are very thrilled with this development and we continue to work towards our vision and goals for the company.
Mr. Baron Night, CEO, further added that "this customer is an international pharmaceutical marketing company and its products include prescription skin care, tablets, capsules, and topical dose form products that are sold through all major distribution channels in the United States which include national and regional wholesalers, distributors, chain drug stores, mass merchandisers, GPO's, managed care organizations and state and government facilities.
Customer's management team, with over 100 years of combined experience, have expertise in the sales, marketing, manufacturing, regulatory, legal, consulting, IT, warehousing, logistics, financial, and consulting aspects of the Pharmaceutical Industry. Sales efforts by this customer's management team, over the course of their careers, have generated gross sales in excess of $1 Billion Dollars. Customer's primary focus is to continually provide the highest levels of quality and service and achieve complete satisfaction in the products they offer. This Customer values industry relationships and is continuously expanding its product offerings."
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Enters-into-Master-Supply-Agreement-with-US-based-Pharmaceutical-Company?id=214753
December 21, 2018
SOHM, Inc., Signs Strategic Alliance With Manufacturing Unit in Southern California and Expands Product Base and Revenue Sources.
Chino Hills, CA – December 21, 2018 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today the signing of a strategic alliance with a manufacturing unit in Southern California, USA. This alliance strengthens both SOHM’s manufacturing capabilities within the US and it’s exports to other countries.
CEO Baron Night expects this alliance to strengthen company’s market penetration in OTC and prescription (Rx) drug products especially in the skin care and cosmeceutical sectors. Revenue growth in key OTC and Prescription (Rx) U.S. markets should also occur. Mr. Night added, “we are confident that this alliance will have a positive impact on SOHM’s revenue growth starting in 2019, will continue to grow over the next several years, and is in alignment with management’s visions and goals.”
Mr. Night further stated, “Our manufacturing alliance partner operates a 20,000 square ft. Southern California facility that is FDA certified and OTC and Prescription (Rx) drug and cGMP compliant. They specialize in product development and the manufacture of skin, hair, and body care products as well as color cosmetics. This manufacturing house not only has over 4500 formulas available and accessible to us but, has the capability to modify these formulas to suit our as well as our client’s needs.”
https://www.sohm.com/2018/12/21/sohm-inc-signs-strategic-alliance-with-manufacturing-unit-in-southern-california-and-expands-product-base-and-revenue-sources/
NOVEMBER 26, 2018
SOHM, INC. ANNOUNCES ITS 3RD QTR. 2018 RESULTS AND UPDATES
CHINO HILLS, NOVEMBER 26, 2018 – SOHM, Inc. (Pink Sheets: SHMN), is a generic Pharmaceutical, Nutraceutical and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories.
Management is very pleased to announce 3rd quarter revenues of $397,688 as of September 30, 2018. Revenue growth for the first nine months of 2018 increased by 228% as compared to the annual gross revenue of $173,955 for the year 2017. A gross profit of $183,134 was realized in just the first nine months of 2018. An increase of 177% when compared to the $103,366 twelve-month gross profit for the year 2017.
Management’s operational and development goals are on track.
Mr. Baron Night, company CEO, added that Company growth was made possible by his predecessor’s continuing focus on adhering to Management’s operational and development goals during the year 2017 and 2018.
Mr. Night states that the company has not issued any stock to anyone including promoters, officers, directors, and/or employees in the last several years. The purpose of the stock issued in April 2018 was to retire financial notes as explained by corporate counsel. Company management has no immediate plans to engage in any major restructuring of its share structure. Every company has revenue growth challenges. We are working towards reducing costs, stabilizing revenue markets, and improving growth.
https://www.sohm.com/2018/11/26/sohm-inc-announces-its-3rd-qtr-2018-results-and-updates/
SEPTEMBER10,2018
SOHM Names Financial Veteran Baron Night as CEO and President
Expert In financial sector for more than 40 years in different industries, SOHM looking forward to getting the expertise of him
CHINO HILLS, SEPTEMBER 10, 2018 – SOHM, Inc. (Pink Sheets: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering many treatment categories announced today the appointment of Baron Night President and CEO for SOHM, Inc. effective immediately. Mr. Night’s appointment fills an important role on SOHM’s team. SOHM believes that Mr. Night’s 40+ years of experience in various industries will be a great asset to the company. Mr. Night has also been named to the Company’s Board of Directors.
Mrs. Swati Shah has voluntarily resigned from the firm as President, CEO and Director effective immediately for personal reasons upon acceptance of Mr. Night’s consent. The Company extends and wishes to express its gratitude for providing her leadership during this recent critical time. The Company wishes her all the best for her new endeavor.
As previously announced, the Company expects pharmaceutical sales to be a significant contributor to revenue and earnings in 2018.
Mr. Night’s thorough experience in providing leadership to various companies and his contacts and experience in emerging markets will strengthen the position of the Company and allow for large scale distribution of generic drug lines,” stated outgoing President Swati Shah.
https://www.sohm.com/2018/09/10/sohm-names-financial-veteran-baron-night-as-ceo-and-president/
September 10, 2018
NV SOS
all officers Remove n Replaced with Mr. Baron Night
https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&nt7=0
SEPTEMBER 21, 2018
SOHM Announces Its Outlook and Action Plans After Corporate Changes.
CHINO HILLS, SEPTEMBER 21, 2018 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical and Cosmeceutical company that produces and markets generic drugs covering many treatment categories is pleased to announce its outlook for remaining year of 2018 and action plan after going through recent corporate changes.
As we have announced last week, Mr. Baron Night was appointed as the sole member of the Board of Directors, President and CEO for SOHM, Inc. SOHM’s management appointment of a new CEO/President was necessary due to SOHM’s previous CEO and President wanted to pursue different career goals and had been discussing this change within for several months. As a matter of fact, outgoing President and CEO was keen on appointing a new CEO and relive her responsibilities so she could pursue her personal goals and vision. Hence the company believes that the changes made brings fresh new leadership to the Company.
Further, Mr. Night stated that his appointment has come at a time when the Company is going through its transition from almost no activities for a few years to more proactive activities in coming days and years. He stated that his educational background of an MBA with finance and 40+ years of employment in various industries will enable him to help build the company to better credibility and transparency. “I am glad to take over the company leadership and I am happy to share my view points and vision about the company,” said Mr. Night.
Mr. Night stated that his prime goal and actions would be to work towards the company vision “Globalè Prospèro” and implement certain actions towards achieving its goal. The Company had previously set a goal to reach certain achievements by year 2020 but due to various hurdles, it has revised this goals to year 2022 or 2024. In the coming weeks after thorough study and consultations and planning, SOHM will provide additional updates.
Mr. Night also said, “The company’s operations will continue as planned by my predecessor for revenues and operations and development and not limited to only manufacturing, sales and marketing and finance but working and analyzing to adopt new technologies in coming days. This could include blockchain or supply chain integration or any other avenues.”
The company currently has manageable capital for its operations, with reduced operational costs. The company is not intending to conduct any reverse split but in coming days/weeks and months, the company will be considering a share buyback program. At the appropriate time, the company may make an announcement, if the company decides to pursue a buyback program after appropriate due diligence and consultation from our legal counsel. The company has not conducted a reverse split since 2008, when new management had taken over the company and was attempting to restructure the company’s capital stock. After a change in management in 2008, the company demonstrated very good growth until 2014, at which time the health of the company’s then-President, the company suffered drastic drop in its revenues. However, during the current year, management is encouraged by the orders it has received from its buyers and believes the future is bright.
The company has received its approval from OTCmarkets.com to use the OTC News & Disclosure Service to upload its financial statements and provide other required disclosures. The company is working with its legal counsel to cause its last two (2) years of financial statements and interim financial statements for the period ended March 31, 2018 to be made publicly available on OTCmarkets.com very shortly. Our March 31, 2018 financials are already published on our website.
There are still some doubts in minds of some of investors about the 108+ million shares of common stock issued by the company in April 2018. The company’s legal counsel clarified that these shares were issued to a financial institution in cancellation of old promissory notes owed by the company and no member of the company’s management received any shares nor were any of them associated with financial institution. Due to a confidentiality clause of the agreement, the company cannot release the name of institution.
The company has remained transparent previously and we are committed for transparency within guidelines and rules and working consistently towards it. “Our operational and revenue generation efforts are ongoing and we are confident of achieving our revenue target for the year 2018 and beyond”, stated Mr. Night, President and CEO.
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing in India as well as strategic alliance with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and was introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To know more about SOHM, Inc., visit www.SOHM.com
https://www.sohm.com/2018/09/21/sohm-announces-its-outlook-and-action-plans-after-corporate-changes/
SHMN FILINGS
https://www.otcmarkets.com/stock/SHMN/disclosure
$$$$ REVENUE $$$$
Revenue $397,688 first nine months of 2018
Quote:
Management is very pleased to announce 3rd quarter revenues of $397,688 as of September 30, 2018. Revenue growth for the first nine months of 2018 increased by 228% as compared to the annual gross revenue of $173,955 for the year 2017. A gross profit of $183,134 was realized in just the first nine months of 2018. An increase of 177% when compared to the $103,366 twelve-month gross profit for the year 2017.
Management’s operational and development goals are on track.
https://www.sohm.com/2018/11/26/sohm-inc-announces-its-3rd-qtr-2018-results-and-updates/
SOHM management announce gross revenue of $ 287.371 for 1st and 2nd qtrs., company's combined gross revenue is approx. 65% more than last fiscal year’s total revenue. We are pleased with results & very confident in our operation and developments. $SHMN
Company Tweets: https://twitter.com/sohminc
July 17, 2018
SOHM, Inc. Reports $180,000 of Total Revenue and a Gross Profit of $95,292 for the First Qtr of 2018
Chino Hills, CA, July 17, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer, release its first Qtr of 2018.
YEAR END 2016 12 months ended Dec 2016 TOTAL REVENUE $124,261; GROSS PROFIT $94,006
YEAR END 2017 12 months ended Dec 2017 TOTAL REVENUE $173,955; GROSS PROFIT $103,366
3 Months Ended March 2018 TOTAL REVENUE $180,837; GROSS PROFIT $95,292
SOHM, Inc.’s Annual Financial for year ending 2016, 2017 and First Qtr 2018 Sohm, Inc.’s Annual Financial for year ending 2016, 2017 and first qtr. which is ended on March 31, 2018. We are glad that we have now released all financials. We also thank all our shareholders for support and patience and as we reiterate management is working towards more actions and determined to update progress in a timely manner moving forward and especially for financials.
https://www.otcmarkets.com/stock/SHMN/news/story?e&id=1128216
"---above maintained by imgoingfishing1"
NEWS
https://www.sohm.com/2017/04/28/sohm-inc-signs-strategic-alliance-with-manufacturing-unit-in-southern-california-to-increase-revenue/
SOHM Inc., Signs Strategic Alliance with Manufacturing Unit in Southern California To Increase Revenue.
Partnerships and Alliances To Strengthen Market Penetration and Revenue Growth in Year 2017 and beyond.
Chino Hills, CA — April 27, 2017
SOHM, Inc. (PINKSHEETS: SHMN), a manufacturer of generic drugs covering all major treatment categories in Pharmaceutical, Nutraceutical and Cosmeceutical drug products announced today that it has signed a strategic alliance with a manufacturing unit in Southern California. This alliance strengthens SOHM’s manufacturing capabilities within the United States for distribution and export to other countries.
The company expects partnerships and alliances to strengthen market penetration and revenue growth in key emerging markets within the United States through its distribution channels. Alliance allows SOHM to double pharmaceutical production capability, reduce costs by several percent, increase profitability and restore its lost revenue from recent years. This alliance will make a positive impact on SOHM’s revenue by the end of Q3.
The strategic alliance with this manufacturing house currently has a range of 90 products covering major therapeutic categories. SOHM will utilize its spare manufacturing capacity of the manufacturing house.
“The manufacturing house facilities can produce all essential products in the dosage forms including tablets, capsules, flavored nutritional powders, sports energy drink powders, oral liquids, ointments, creams with excellent packing facilities, this will allow SOHM, Inc, USA to fulfill its growing market demand in the coming season and achieve the manufacturing volume growth needed to fulfill future purchase orders. This step also align company with current focus of USA to “Manufacturer in USA” by the government of USA and this will help to reduce operating costs and increase profitability.”
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
https://globenewswire.com/news-release/2017/11/29/1210569/0/en/SOHM-Inc-Cancellation-of-Reverse-Stock-Split.html
Cancellation of Reverse Stock Split
Chino Hills, CA, Nov. 28, 2017 (GLOBE NEWSWIRE)
SOHM, Inc. (PINKSHEETS: SHMN), announced today that its Board of Directors has decided to abandon and cancel the reverse stock split that was approved by the Board of Directors and the Company’s shareholders last year.
SOHM, Inc. announce today that “We are pleased to announce due to the obvious recent renewed support and confidence in the company and its management, it is in the best interest of the company, its shareholders and Investors to cancel the proposed reverse split of the common stock announced last year.” Recent support from operations and market awareness has further inspired company management to restore SOHM, Inc. to its former glory, benefitting investors and shareholders who have stood firmly by the company. SOHM presently has approximately 1.25 billion shares of common stock issued & outstanding SOHM Management has taken note of significant trade activity of its shares, and is very pleased with the recent movement in the company operation.
Further, company stated that company’s promoters or directors have not sold any of their stocks and have not done so for the last several years keeping the confidence in the company’s operations and not intending to sell any stocks currently.
Company is going to take appropriate actions with authorities to update the recent development and announcements.
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a global presence and marketing plan that assure continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing in India. Although SOHM’s generic pharmaceuticals are exported globally and was introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia along with USA.
Forward-Looking Statements
This press release contains many forward-looking statements such as “project,” “plan,” “can,” etc. Such statements are subject to possible uncertain risks that may vary actual results from those intended in or expressed by the forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact:
SOHM, Inc.
714-522-6700
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Chino Hills, CA, Nov. 29, 2017 (GLOBE NEWSWIRE)
I-Prolec™: Maximum Protein, Maximum Uptake
SOHM, Inc. (Pink Sheets: SHMN) is planning to launch a unique protein supplement “I-Prolec™” in to the American multibillion dollar supplement market. This unique product was a category defining product in India, and has very has good response from its consumers. I-Prolec™ is one of a long list of innovative products coming through the Sohm pipeline.
“This unique product, I-Prolec™, is formulated keeping in mind all the age groups and genders. I-Prolec™ will help people who have protein deficiency as well as athletes who need extra proteins, especially for those who adhere to a vegetarian diet”.
This special formulation of I-Prolec™ comes with and easy to absorb Vitamin B6, Vitamin B9, Iron (In the form of L Methyl Folate), plus all the minerals and vitamins that would make healthy living a reality. It has 23 different vitamins in a single dose. The fact that a single serving dosage is good enough for confirmed patient compliance made I-Prolec™ an instant hit amongst leading Gynecologists and Pediatricians in India as well as in retail nutraceutical market segment.
SOHM team believes that I-Prolec™ is not only a winning formula developed locally, but is also the most prolific protein supplement that SOHM is launching in USA and other important Global Markets in the coming months. With the introduction of I-Prolec™, SOHM will open a new stream of revenue. I-Prolec™ and products that are in the pipeline in this category would further consolidate the stability in revenue stream and ever-growing revenue generation in the coming months and especially in year 2018.
Company plans to sell and market this products through its distribution channels as well as retails online chain stores like Amazon and other reputable online stores.
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a global presence and marketing plan that assure continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing in India. Although SOHM’s generic pharmaceuticals are exported globally and was introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia along with USA.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
https://globenewswire.com/news-release/2017/12/05/1229320/0/en/SOHM-Inc-Announces-Relaunch-of-Flagship-Skincare-Product-in-USA.html
SOHM, Inc., Announces Relaunch of Flagship Skincare Product in USA
Chino Hills, CA , Dec. 05, 2017 (GLOBE NEWSWIRE)
SOHM, Inc., (PINKSHEETS: SHMN) announced today a relaunch of its flagship skincare product FoHM by SOHM™, a rejuvenating, cleansing, and clarifying facial foam powered by SOHM’s proprietary formula Salic2™. This product was launched at an “after Oscar Party” in 2013 for the US market and had good market response however due to unavoidable circumstances, SOHM was not able to fully capitalize on its momentum.
FoHM by SOHM™ is a foaming facial cleanser and clarifier powered by Salic2™—SOHM’s propriety salicylic acid formulation. Originally, within the South Asian markets, this product was available only from dermatologists and doctors.
U.S. Relaunch of FoHM by SOHM™
So why transform a successful clinical product into an OTC (over-the-counter) product for U.S. consumption? “A number of things came together for us”
“First, we recognized that the American market is more mature and experienced with this type of product than markets we have been selling to in developing countries where acne, blackheads, and other skin conditions also are a problem. This will be manufactured within USA by SOHM’s Strategic Alliance company in Southern California.
“Second, in America we are taking the product direct to the consumer through online retail market places such as Amazon, and SOHM’s own online store. We are also in process with other online and brick and mortar retail chain stores for distribution and retail selling.
“However, third and most important to our decision was our innovation of a new delivery system. Normally, a 2% salicylic acid formulation is delivered as a gel or a cream. However, the Salic2 formula in FoHM by SOHM™ is a gentle but powerful foam delivery system that is perfect for the American consumer. Not only is it unique, but it is a more effective formulation than has been available.”
US OTC skin care market is multi-billion-dollar and with relaunch of this product, SOHM will create a new paradigm of success for it in the multi-billion-dollar skincare market, a space which “is expected to increase by 10%… driven by facial care,” according to Euromonitor International. We are especially enthusiastic about the unique delivery system of FoHM by SOHM™: a foam applicator that is not only convenient for women, but it makes this a product more likely to be used by men. We know that the more a product fits into the daily habits of a male consumer, the more successful he is to use it. Most women use skincare products, but most men don’t. At least, not before FoHM by SOHM™, which can be used by men for shaving!
With above introduction of product, SOHM expects fairly good organic growth in company revenues, its operation and bring full stability and growth in coming months and years.
https://globenewswire.com/news-release/2017/12/05/1229369/0/en/SOHM-Inc-TO-ENTER-ICO-BITCOIN-MARKET.html
SOHM, Inc., Announces $0.5m Purchase Order for a range of Pharmaceutical products in 2018.
CHINO HILLS, CA—December 7, 2017
SOHM, Inc. (PINKSHEETS: SHMN) is a globally-known generic pharmaceutical manufacturer, developer and marketer of a wide range of products serving a broad segment of the therapeutics market.
SOHM has received a purchase order, with an initial order of more than $0.5 million to supply a range of pharmaceutical products to one of its east coast customers, that will run through the end of 2018.
This new purchase order comes from a current customer that has executed purchase orders with SOHM through the end of 2017.
A spokesperson for SOHM, Inc., said, “SOHM is very pleased to have received this order from this customer that supplies retail and pharmacy networks all across the United States. This represents an annualized commitment to purchase and distribute 6 products other than SOHM products while providing SOHM a lucrative base to the huge American market for Generic Pharmaceuticals.
SOHM’s spokesperson said completion of this order would assure that SOHM achieves its target for higher revenue growth in 2018 compared to previous years.
https://globenewswire.com/news-release/2018/01/19/1297892/0/en/SOHM-Inc-Executes-Non-Toxic-Funding-Commitment-with-Institutional-Investor-for-Expansion-of-Core-Business-to-Adopt-Blockchain-Technologies.html
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
SOHM, INC
Social Media, Corporate Info.
TWITTER FEED: https://twitter.com/sohminc?lang=en
FACEBOOK FEED: https://www.facebook.com/sohminc/
PRESS RELEASES (SOHM Website): https://www.sohm.com/category/press-releases/
OTC MARKETS: https://www.otcmarkets.com/stock/SHMN/profile
NVSOS: http://nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&nt7=0
NVSOS ACTIONS/AMENDMENTS: http://nvsos.gov/SOSEntitySearch/corpActions.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&CorpName=SOHM%2c+INC.
Contact info.
Website: http://www.sohm.com
Phone: (714) 522-6700
Address:
4195 Chino Hills Pkway
Ste 675
Chino Hills, CA 91709
Email: info@sohm.com
.png)
-~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ "---below maintained by Blue"~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
SOHM, INC
TICKER: SHMN
Social Media, Corporate Info.
SOHM Website: https://www.sohm.com/
TWITTER FEED: https://twitter.com/sohminc?lang=en
FACEBOOK FEED: https://www.facebook.com/sohminc/
OTC MARKETS: https://www.otcmarkets.com/stock/SHMN/profile
NVSOS: http://nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&nt7=0
NVSOS ACTIONS/AMENDMENTS: http://nvsos.gov/SOSEntitySearch/corpActions.aspx?lx8nvq=DraWvY7hzMLlBgmKhjdRSQ%253d%253d&CorpName=SOHM%2c+INC.
----------------------------------------------
ABOUT SHMN
Sohm, Inc. (PinkSheets: SHMN) is a globally recognized Pharmaceutical company focused on developing, manufacturing and distributing Generic, Branded Generic, Private label, and Sohm innovated Pharmaceuticals, Cosmeceuticals and Nutraceutical products. The Company has its U.S. headquarters located in Chino Hills, CA, and have various strategic alliances with its manufacturing partners.
Sohm Inc. has voted the fastest growing generics prescription drug manufacturer in 2012 at the 30th All India Conference of National Integrated Medical Association. Sohm develops, manufactures and markets generic, branded generic, legacy brands, and Over-the-Counter (OTC) products in several countries.
Sohm is committed to strict adherence to all applicable regulatory requirements and to the highest degree of industry standards. We are committed to maintaining quality by all employees at all levels throughout our corporation. Sohm ensures compliance by continuous assessment and monitoring of the output of the existing quality systems and application of evolving industry guidelines and regulations including all WHO-CGMP and USFDA guidelines.
Sohm also offers and encourages businesses of any size all over the world to participate with the private labeling of generic pharmaceutical, cosmeceutical and nutraceutical products as part of its ongoing effort to integrate businesses and inspire global prosperity.
----------------------------------------------------------------
SOHM, Inc. Announce Interim Shareholder update
09/11/2020 posted in Press Releases Chino Hills, CA – September 11, 2020 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today some of the developments with the company and their re-entry into the US OTC retail, prescription, contract manufacturing, and white label manufacturing and marketing space.
Mr. Baron Night-CEO announced today that the company has continued with the development and introduction of 5 new products into its product line while maintaining consistency with the company’s outlook and strategic plan. All manufacturing is in the USA. Our products are currently being marketed and sold in the USA.
1. Nail Renovar-Nail Fungus treatment. This global market is projected to reach 6.7 Billion by 2026.
2. Hand Sanitizer Spray with Aloe Vera- Personal Care
3. Anti-Microbial Multi-Purpose Spray- Personal Care
4. Anti-Microbial Hand Soap- Personal Care and
5. Non-Alcoholic Hand Sanitizer Gel-Personal Care
SOHM will be introducing some additional new products in-line with its Globalè Prospèro Vision 2024 in the coming weeks/months.
The company is still working and generating revenues with its B2B private label prescription product customers in conjunction with its Business to Consumer segments.
The current pandemic has impacted everyone. We have taken steps to balance health concerns with revenues. Mr. Night informed.
Mr. Night-CEO has further stated that the company management has no plans to conduct any reverse split of shares as announced in January of 2018.
The company has not issued any shares to anyone including promoters, officers, directors, and/or employees in the last several years. SOHM also has not retired any financial notes through the issuance of any shares in the year 2019 and to date during the current year. The company issued totaling approx. 27.7 million shares restricted shares in the fourth quarter of 2019 and the second quarter of 2020 for attorney services.
The company and management will honor all previously announced commitments made to all stakeholders.; Mr. Night added.
-------------------------------------------------------------------------------------------------
SHMN~ in the FDA list: 009303848 Sohm,Inc., USA SHMN
https://www.fda.gov/downloads/AboutFDA/WorkingatFDA/Ethics/UCM540392.pdf
--------------------------------------------------------------------
SHMN has over 300 generic drugs
Pharmaceutical
Analgesic
Antibiotics
Anti-Cold
Anti-Flammatory
Beta-Lactum Antibiotics
Capsules
Drops
Injections
Suspension
Syrups
Cosmeceutical
FOHM
Nutraceutical
Capsule
Drop
Suspension
Syrup
Tablets
https://www.sohm.com/product/antibiotics/
https://www.sohm.com/product/analgesic/
--------------------------------------------------------------------
SHMN~ Drug List~ : NDC Labeler - SOHM Inc.
The following table lists the NDC drug codes by SOHM Inc.:
NDC Trade Name Labeler Name
50405-0110 Salic-2 SOHM Inc.
50405-0002 SohMed Acid Reducer SOHM Inc.
50405-0005 SohMed Alertness Aid SOHM Inc.
50405-0004 SohMed Allergy SOHM Inc.
50405-0003 SohMed Allergy Sinus SOHM Inc.
50405-0006 SohMed Cold Relief SOHM Inc.
50405-0001 SohMed Extra Strength SOHM Inc.
50405-0007 SohMed Pain Relief PM SOHM Inc.
50405-0008 SohMed Pain Reliever SOHM Inc.
50405-0009 SohMed Sinus Sohm Inc.
https://www.findacode.com/ndc/labelers/SOHM_Inc.
--------------------------------------------------------------------
SHMN ~Generic Drug List ~
(1)..Analgesic
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Sonim 100 Tablet Nimesulide – 100 Mg. 10 X 10 Blister
2 Sonim 200 Tablet Nimesulide – 200 Mg. 10 X 10 Blister
3 Sonim P Tablet Nimesulide – 100 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
4 Sonim BT Tablet Nimesulide In Betacyclodextrin 10 X 10 Blister
5 Sonim Suspension Nimesulide Suspension 50 ML. Bottle
6 Sonim P Suspension Nimesulide Paracetamol Susp 50 ML. Bottle
7 K-Gesic Tablet Ibuprofen 400 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
8 K-Gesic Suspension Ibuprofen 100 Mg. Paracetamol – 162.5 Mg. 50 ML. Bottle
9 Allmol 500 Tablet Paracetamol – 500 Mg. 10 X 10 Blister
10 Allmol Suspension Paracetamol Suspension 50 ML. Bottle
11 Dipagesic Tablet Diclofenac – 50 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
12 Dipagesic – S Tablet Diclofenac – 50 Mg. Serritiopeptidase – 10 Mg. 10 X 10 Blister
13 Parci Tablet Aceclofenac 100 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
14 Kampitol Tablet Tramadol 50 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
https://www.sohm.com/product/analgesic/
------------------------------------------------------------------------------
(2).. Antibiotics
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Ampicin Capsule / Tablet Ampicillin – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Blister
2 Ampicin Dry Syrup Ampicillin Dry Syrup 30 ML. Bottle
3 Ampicin-CL Capsule Ampicillin Cloxacillin – 125 Mg./250 Mg./500 Mg. 10 X 10 Blister
4 Ampicin-CL Dry Syrup Ampicillin Cloxacillin – Dry Syrup 30 ML. Bottle
5 Somox Capsule / Tablets Amoxicillin – 125 Mg / 250 Mg. / 500 Mg./td> 10 X 10 Blister
6 Somox Dry Syrup Amoxicillin – Dry Syrup 30 ML. Bottle
7 Somiclox Capsule Amoxicillin Cloxacillin – 250 Mg. / 500 Mg. 10 X 10 Blister
8 Somiclox Dry Syrup Amoxicillin Cloxacillin – Dry Syrup 30 ML. Bottle
9 Somox – CV Tablet Amoxicillin Clavulanic Acid – 325 Mg./650 Mg./1000 Mg. 10 X 10 Alu Alu
10 Somox – CV Dry Syrup Amoxicillin Clavulanic Acid – Dry Syrup 30 ML. Bottle
11 Somexin Capsule / Tablets Cephalaxine – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Blister
12 Somexin Dry Syrup Cephalaxine – Dry Syrup 30 ML. Bottle
13 Fedro Capsule / Tablet Cefadroxyl – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Alu Alu
14 Fedro Dry Syrup Cefadroxyl – Dry Syrup 30 ML. Bottle
15 Foxim Capsule / Tablet Cefuroxime – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Alu Alu
16 Foxim Dry Syrup Cefuroxime – Dry Syrup 30 ML. Bottle
17 Sozim Tablet Cefixime – 50 Mg. / 100 Mg. / 200 Mg. 10 X 10 Alu Alu
18 Sozim Dry Syrup Cefixime – 50 Mg.- Dry Syrup 30 ML. Bottle
19 Sozim Clav Tablet Cefixime Clavulanic Acid 10 X 10 Alu Alu
20 Sozim Clav Dry Syrup Cefixime Clavulanic Acid – Dry Syrup 30 ML. Bottle
21 Sopod Tablet Cefpodoxime -50 Mg. / 100 Mg. / 200 Mg. 10 X 10 Alu Alu
22 Sopod Dry Syrup Cefpodoxime -Dry Syrup 30 ML. Bottle
23 Sopod Clav Tablets Cefpodoxime Clavulanic Acid 10 x 10 Alu Alu
https://www.sohm.com/product/antibiotics/
------------------------------------------------------------------------------------------
(3)... Anti-Cold
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Karicet Tablet Cetirizine DiHcl – 10 Mg. 10 X 10 Blister
2 Somcold Tablet Cetirizine PPA PCM 10 X 10 Blister
3 Alyzyn Tablet Levocetrizine Hcl. – 5 Mg. 10 X 10 Blister
4 Alyzyn D Tablet Levocetrizine Hcl. – 5 Mg. Phenylepherine 10 Mg. 10 X 10 Blister
5 PC-PC Tablet Anti Cold Tablet 50 ML. Bottle
6 PC-PC – S Tablet Para PPM Cetri Dext Caffine 10 X 10 Blister
7 Coldtop Tablet Cetrizine DiHcl PPA CPM 10 X 10 Blister
8 Coldtop Suspension Cetrizine DiHcl PPA CPM 50 ML. Bottle
9 Vericold Syrup Dextro Cet PPA 100 ML. Bottle
10 Vericold – PR Syrup Terbutalin Ambroxol Guaph. Menthol 100 ML. Bottle
11 Vericold – Ped Suspension Paracetamol PPM Dextro CPM 50 ML. Bottle
12 Vericold Drop CPM Phenylepherine 30 ML. Bottle
13 Vericold PDS Suspension Paracetamol PPM Dextro CPM 50 ML. Bottle
14 Kardryl Syrup Diphen Sod. Cit. Ammonium Menthol 100 ML. Bottle
https://www.sohm.com/product/anti-cold/
----------------------------------------------------------------------------------------------
(4)... Anti-Flammatory
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Sonim 100 Tablet Nimesulide – 100 Mg. 10 X 10 Blister
2 Sonim 200 Tablet Nimesulide – 200 Mg. 10 X 10 Blister
3 Sonim P Tablet Nimesulide – 100 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
4 Sonim BT Tablet Nimesulide In Betacyclodextrin 10 X 10 Blister
5 Sonim Suspension Nimesulide Suspension 50 ML. Bottle
6 Sonim P Suspension Nimesulide Paracetamol Susp 50 ML. Bottle
7 K-Gesic Tablet Ibuprofen 400 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
8 K-Gesic Suspension Ibuprofen 100 Mg. Paracetamol – 162.5 Mg. 50 ML. Bottle
9 Allmol 500 Tablet Paracetamol – 500 Mg. 10 X 10 Blister
10 Allmol Suspension Paracetamol Suspension 50 ML. Bottle
11 Dipagesic Tablet Diclofenac – 50 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
12 Dipagesic – S Tablet Diclofenac – 50 Mg. Serritiopeptidase – 10 Mg. 10 X 10 Blister
13 Parci Tablet Aceclofenac 100 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
14 Kampitol Tablet Tramadol 50 Mg. Paracetamol – 500 Mg. 10 X 10 Blister
https://www.sohm.com/product/anti-flammatory/
---------------------------------------------------------------------------------------------
( 5)..Beta-Lactum Antibiotics
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Ampicin Capsule / Tablet Ampicillin – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Blister
2 Ampicin Dry Syrup Ampicillin Dry Syrup 30 ML. Bottle
3 Ampicin-CL Capsule Ampicillin Cloxacillin – 125 Mg./250 Mg./500 Mg. 10 X 10 Blister
4 Ampicin-CL Dry Syrup Ampicillin Cloxacillin – Dry Syrup 30 ML. Bottle
5 Somox Capsule / Tablets Amoxicillin – 125 Mg / 250 Mg. / 500 Mg./td> 10 X 10 Blister
6 Somox Dry Syrup Amoxicillin – Dry Syrup 30 ML. Bottle
7 Somiclox Capsule Amoxicillin Cloxacillin – 250 Mg. / 500 Mg. 10 X 10 Blister
8 Somiclox Dry Syrup Amoxicillin Cloxacillin – Dry Syrup 30 ML. Bottle
9 Somox – CV Tablet Amoxicillin Clavulanic Acid – 325 Mg./650 Mg./1000 Mg. 10 X 10 Alu Alu
10 Somox – CV Dry Syrup Amoxicillin Clavulanic Acid – Dry Syrup 30 ML. Bottle
11 Somexin Capsule / Tablets Cephalaxine – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Blister
12 Somexin Dry Syrup Cephalaxine – Dry Syrup 30 ML. Bottle
13 Fedro Capsule / Tablet Cefadroxyl – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Alu Alu
14 Fedro Dry Syrup Cefadroxyl – Dry Syrup 30 ML. Bottle
15 Foxim Capsule / Tablet Cefuroxime – 125 Mg. / 250 Mg. / 500 Mg. 10 X 10 Alu Alu
16 Foxim Dry Syrup Cefuroxime – Dry Syrup 30 ML. Bottle
17 Sozim Tablet Cefixime – 50 Mg. / 100 Mg. / 200 Mg. 10 X 10 Alu Alu
18 Sozim Dry Syrup Cefixime – 50 Mg.- Dry Syrup 30 ML. Bottle
19 Sozim Clav Tablet Cefixime Clavulanic Acid 10 X 10 Alu Alu
20 Sozim Clav Dry Syrup Cefixime Clavulanic Acid – Dry Syrup 30 ML. Bottle
21 Sopod Tablet Cefpodoxime -50 Mg. / 100 Mg. / 200 Mg. 10 X 10 Alu Alu
22 Sopod Dry Syrup Cefpodoxime -Dry Syrup 30 ML. Bottle
23 Sopod Clav Tablets Cefpodoxime Clavulanic Acid 10 x 10 Alu Alu
https://www.sohm.com/product/beta-lactum-antibiotics/
--------------------------------------------------------------------------------------------
(6).. Capsules
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Amodix Cap Amoxycillin Trihydrate 250 Mg. Dicloxacillin Sodium 250 Mg. 10 X 10 Alu Alu
2 Rabitus-DSR Cap Rabeprazole Sodium 20 Mg Domperidone 30 Mg 10 X10 Alu Alu
3 Rabitus-M Cap Rabeprazole Sodium 20 Mg Mosapride Citrate Dihydrate 15 Mg. 10 X 10 Alu Alu
4 Omitus Cap Omeprazole 20Mg. 10 X 10 Alu Strip
5 Omitus-D Cap Omeprazole 20Mg. Domperidon 10Mg. 10 X 10 Alu Strip
6 UK-Ron Cap Haematinic Cap 10X2X15 ALU STRIP
7 Wezol Cap Vit Mineral Antioxidant 5X2X15 Alu Strip
8 UK-Sul Cap Vitamin B Complex 10X5X10 Alu Strip
9 Sizocid-20 Cap Omeprazole Cap 10X3X10 Alu Strip
10 Sizocid- OD Cap Omeprazole Domperidone Cap 10X2X15 Alu Strip
11 Tetra Cap Tetracycline 250 Mg Cap 3X10X10 Alu Strip
12 U-Full-Z Cap Carbonyl Iron Zinc Cap 5X2X15 Alu Strip
13 Uvee-Tal Cap Multivitamin Multimineral Cap 5X2X15 Alu Strip
14 UK-Top Cap Multivitamin Antioxidant Cap 3X2X15 Alu Strip
https://www.sohm.com/product/capsules/
----------------------------------------------------------------------------
(7)... Drops
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Vericold Drops CPM PHENYLEPHERINE 30 ML BOTTLE
2 Aspa Drop DICYCLOMINE SIMETHICONE 15 ML BOTTLE
3 ASPA-EN DROP SIMETHICONE ALPHA AMYLASE DIL OIL ANNISE FENNEL OIL 15 ML BOTTLE
https://www.sohm.com/product/drops/
----------------------------------------------------------------------
(8)--- Injections
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Inj. Amulet 100 / 250 / 500 Amikacin 100 Mg / 250 Mg. / 500 Mg. 2 ml 2 ML VIAL 50
2 Inj. Amulet 500 mg 10ml Amikacin 100 Mg /2 ml 10 ML VIAL 25
3 Inj. Anmycin 80 mg Gentamicin Sulphate 40mg / ml 2ML / 10 ML / 30 ML VIAL 100
4 Inj. Anagesic Diclofenac Sodium 25mg / ml 30ML VIAL 25
5 Inj. Anagesic Diclofenac Sodium 25mg / ml 3ML AMP 100
6 Inj. Arther Alph-Beta Arteether 2ML AMP. 1X3td>
7 Inj. Dexahil Dexamethasone Phosphate 4mg / ml 2ML / 10 ML / 30 ML VIAL 100
8 Inj. Jetquin Chloroquin 40mg/ ml 5ML AMP 25
9 Inj. Jetquin Chloroquin 40mg / ml 30ML VIAL 25
10 Inj. Ranil Ranitidine 25mg / ml 2ML AMP. 100
11 Inj. Ranil Ranitidine 25mg / ml 10ML VIAL 25
12 Inj. Anatrol 2ml Ondansetron Hcl 2mg / ml 2ML AMP. 100
13 Inj. Anatron 10 ml Ondansetron Hcl 2mg / ml 10ML VIAL 25
14 Inj. Anadol 2ml Tramadol Hcl 50mg / ml 2ML AMP. 100
15 Inj. Anclox 500mg / 1 gm Ampicillin250mg Cloxacillin 250mg 500MG / 1GM VIAL 20
16 Inj. Trione 250 mg / 500 mg / 1 gm Ceftriaxone 250mg / 500 Mg. / 1 Gm 250ML VIAL 20
17 Inj. Typhoon 250 mg / 500 mg / 1 gm Cefotaxime 250mg / 500 Mg. / 1 Gm 250MG VIAL 20
18 Inj. Cefthil 250 mg / 1 gm Ceftazidime 250 Mg / 1 Gm 250MG VIAL 20
19 Inj. C.S.Plus 1gm Sulbactum / Cefoperazone Sod.500mg 1 GM VIAL 20
https://www.sohm.com/product/injections/
------------------------------------------------------------------------
(9).. Suspension
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Somcold Susp. PARECETAMOL CETIRIZINE PHENYL EPHERINE 60 ML BOTTLE
2 Sonim-P Susp. PARACETAMOL NIMESULIDE 50 ML BOTTLE
3 Vericold-PDS Susp – – –
4 Azima Susp. AZITHROMYCINE 15 ML BOTTLE
5 U-Nice Susp. Nimesulide Susp. 60 ML BOTTLE
6 U-Nice-P Susp. Nimesulide Paracetamol Susp. 60 ML BOTTLE
7 Allmol Susp. Paracetamol Susp. 60 ML BOTTLE
8 PC PC Susp. Anticold Susp. 60 ML BOTTLE
9 Sizocid -MPS Susp. Antacid Susp. 170 ML BOTTLE
10 U-Cal Susp. Calcium Susp. 200 ML BOTTLE
https://www.sohm.com/product/suspension/
-----------------------------------------------------------------
(10).. Syrups
This is a Pharmaceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 SOZIM DRY SYP CEFIXIME DRY SYRUP 30 ML BOTTLE
2 SOPOD DRY SYP. CEFPODOXIME DRY SYRUP 30 ML BOTTLE
3 Vericold Syrup DEXTROMETHO PHENYLEPHERINE CETIRIZINE 100 ML BOTTLE
4 Vericold – PR syrup TERBUTALINE AMBROXOL GUAIPHENESIN 100 ML BOTTLE
5 Vericold -PED syrup PARACETAMOL DEXTRO CPM PHENYLEPHERINE 60 ML BOTTLE
6 Care-Of Syp. Dextr Cetir Ppa Cough Syp. 100 ML BOTTLE
7 Kof-Ca Syp. Cpm Sod Citamo Cough Syp. 100 ML BOTTLE
8 UK-Ron Syp. Haematanic Syp. 200 ML BOTTLE
9 UK-Ron Syp. Haematanic Syp. 300 ML BOTTLE
10 UK-Sul Syp. Iron Vitamin B Complex Yp 200 ML BOTTLE
11 K-Cyp-Grow Syp. Cyproheptadin Syp. 200 ML BOTTLE
12 Wezol Syp. Unique Vitamin Mineral Syp 200 ML BOTTLE
13 Carekof Syp. Ambroxol Ter But Gua Menthol Syp 100 ML BOTTLE
14 Uvzyme Syp. Enzyme Syrup With Sorbitol Soln 200 ML BOTTLE
15 Kardryl Syp. Roxithromycin 50 Mg Syp. 30 ML BOTTLE
16 UKvit Syp. B Complex 200 ML BOTTLE
17 Cold Top Syp. Cet Ppm Cpm Syp. 60 ML BOTTLE
18 Kardryl Syp. Diphen Sod Cit Amonium Menthol 60 ML BOTTLE
19 Kardryl Syp. Diphen Sod Cit Amonium Menthol 100 ML BOTTLE
20 Pruof OZ Syp. Ofloxacin Ornidazole 30 ML BOTTLE
https://www.sohm.com/product/syrups/
-------------------------------------------------------------------------------
(11) .. Capsule
This is a Nutraceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Feronika Cap CARBONYL IRON FOLIC VITAMIN-B6 ZINC 10X10 BLISTER
2 Progi Cap PRE BIOTIC AND PRO BIOTIC CAPSULES 10X10 BLISTER
3 Lycosom Cap LYCOPENE VITAMINS ANTI OXIDENTS 10X10 BLISTER
https://www.sohm.com/product/capsule/
-----------------------------------------------------------------------------------------
(13).. Tablets
This is a Nutraceutical product
Sr. No. Product Name Composition Pack Packaging Type
1 Somvit Tab MULTI VITAMINS ANTI OXIDENTS 10X10 BLISTER
2 Somizyme Tab DIGESTIVE ENZYME 10X10 BLISTER
3 Calcika Tab CALCIUM WITH VITAMIN D3 10X10 BLISTER
https://www.sohm.com/product/tablets/
----------------------------------------------------------------------------
Shop
Showing all 7 results
Default sorting Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low
SHMN Share structure as of 09/03/2020
Authorized: 2,000,000,000
Outstanding Shares: 1,575,576,407
Restricted: 327,792,017
UnRestricted 1,247,784,390
https://www.otcmarkets.com/stock/SHMN/security
------------------------------
SHMN share structure as of 12/31/2015
Authorized 2,000,000,000
Outstanding shares 1,546,636,529
page 14
https://backend.otcmarkets.com/otcapi/company/financial-report/209360/content
--------------------------------------------------------------------------------------------------
-SHMN~ posted Net PROFIT 52,038 Dollars Up to Q3, 2018
https://www.sohm.com/2018/11/26/sohm-inc-announces-its-3rd-qtr-2018-results-and-updates/#.W_w_mM_HvvE.twitter
https://backend.otcmarkets.com/otcapi/company/financial-report/209365/content
--------------------------------------------------------------------
SHMN~ NO R/S~ The management is not intending to conduct any reverse split
but the company will be considering a share buyback program.
https://www.otcmarkets.com/stock/SHMN/news/EQS-News-SOHM-Inc-Announce-Share-Holder-update-and-Outlook-for-2019?id=215967
--------------------------------------------------------------------
SHMN~ SHARE BUYBACK WILL TAKE PLACE UNTIL FEBRUARY 28, 2021
The buyback program as currently planned will take place between March 1, 2019 and February 28, 2021, with an initial target of 10% of the current outstanding shares of SOHM, Inc. common stock (approximately 154,000,000 shares), with not less than 50% to be retired. Pursuant to the safe harbor provisions of Rule 10b-18, these shares will be acquired by SOHM on the public market, and will be subject to the manner of purchase, timing, price, and volume restrictions specified therein.
https://www.otcmarkets.com/stock/SHMN/news/Sohm-Inc-Announces-Shares-Buyback-Program?id=219520
--------------------------------------------------------------------
New Management SHMN Names Financial Veteran Baron Night as CEO and President as of 09/10/2018
Expert In financial sector for more than 40 years in different industries, SOHM looking forward to getting the expertise of him
https://www.sohm.com/2018/09/10/sohm-names-financial-veteran-baron-night-as-ceo-and-president/#.W5akGCoDvdc.twitter
--------------------------------------
Contact info.
Website: http://www.sohm.com
Phone: (714) 522-6700
Address:
4195 Chino Hills Pkway
Ste 675
Chino Hills, CA 91709
Email: info@sohm.com
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~"---above maintained by Blue."~~~~~~~~~~~~~~~~~~~~~~~~~~~